Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(11 months ago) |
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
18
United States
10
European Union
4
Australia
4
Austria
4
Japan
3
Canada
3
New Zealand
3
Spain
3
Germany
3
Mexico
2
Korea, Republic of
2
Brazil
2
China
2
South Africa
1
Israel
1
Denmark
1
Portugal
1
Poland
1
Hong Kong
1
Argentina
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6978945 | PADAGIS US | Dispensing device |
Jul, 2022
(10 months ago) |
Market Authorisation Date: 27 July, 2007
Treatment: NA
Dosage: SPRAY;TRANSDERMAL
5
Australia
2
New Zealand
2
Japan
2
Korea, Republic of
1
Canada
1
Mexico
1
Hungary
1
Russia
1
United States
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11497709 | THERAPEUTICSMD INC | NA |
Nov, 2032
(9 years from now) | |
US9289382 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10537581 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11246875 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11241445 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10835487 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10806697 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11351182 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US11304959 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(9 years from now) | |
US10668082 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
US11065197 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
US11123283 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
US11116717 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
US10568891 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
US10888516 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(10 years from now) | |
US10471072 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(10 years from now) | |
US9180091 | THERAPEUTICSMD INC | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(10 years from now) | |
US10258630 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
US10398708 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(10 years from now) | |
US11266661 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(10 years from now) |
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
92
United States
19
Australia
17
Japan
12
European Union
10
Korea, Republic of
10
Canada
9
Mexico
8
Brazil
7
Russia
4
Israel
4
Argentina
2
Croatia
2
Spain
2
Poland
2
Hungary
1
Portugal
1
RS
1
South Africa
1
Lithuania
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) | |
US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) | |
US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) |
Market Authorisation Date: 29 October, 2012
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
6
United States
3
Japan
2
Russia
2
European Union
1
Canada
1
Mexico
1
Argentina
1
Denmark
1
Portugal
1
Spain
1
Uruguay
1
Taiwan
1
Korea, Republic of
1
Chile
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7018992 | NOVO NORDISK INC | Hormone composition |
Sep, 2022
(8 months ago) |
Market Authorisation Date: 26 March, 1999
Treatment: Treatment of atrophic vaginitis due to menopause
Dosage: TABLET;VAGINAL
6
Denmark
5
United States
3
European Union
2
Germany
2
Spain
2
Japan
1
Cyprus
1
Australia
1
Portugal
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic